Familial dysautonomia (FD) is a recessive neurological disorder that affects the development of the sensory and autonomic nervous system. The gene defect appears to be limited to the Ashkenazi Jewish population, where the carrier frequency is 1 in 30. One hundred and ninety-one marker loci representing all autosomes were tested for linkage with the FD genetic defect in 23 families. A combination of pairwise and multipoint analyses excluded the FD gene from at least 60% of the autosomal genome. The program EXCLUDE predicted regions of chromosomes 2, 4, 5q, 9, or 10 as the most promising locations for future analyses.
Familial dysautonomia (FD), or the Riley-Day syndrome, is a rare inherited neurological disease affecting the development and survival of sensory, sympathetic, and some parasympathetic neurones.1'3 It is the most common and best known of a group of rare disorders, termed congenital sensory neuropathies, that are characterised by widespread sensory and variable autonomic dysfunction. Patients with FD are affected from birth with a variety of symptoms such as decreased sensitivity to pain and temperature, vomiting crises, and cardiovascular instability, all of which might result from a deficiency in a neuronal growth factor pathway.45 Diagnosis of FD is based on the following cardinal criteria: absence of fungiform papillae on the tongue, absence of flare after injection of intradermal histamine, decreased or absent deep tendon reflexes, and absence of overflow of emotional tears. 2 3 Neuropathological findings have clearly differentiated FD from other congenital neuropathies. 2 The disorder has autosomal recessive inheritance with complete penetrance and currently appears to be confined to persons of Ashkenazi Jewish descent. 6 In this population, the estimated carrier frequency is 1 in 30 with a disease incidence of 1 in 3600 live births. 7 The clear cut pattern of transmission, apparent restriction to one ethnic population, straightforward diagnosis, and lack of confounding phenocopies suggest that all cases of FD might have descended from a single founder mutation. 2 Chromosomal localisation of the gene causing FD would facilitate genetic counselling and prenatal diagnosis in affected families. Subsequent delineation of closely linked markers which may show strong linkage disequilibrium with the disorder and, ultimately, identification of the defective gene could allow screening of the entire at risk population to identify carriers, and potentially reduce the incidence of new cases. Consequently, we have sought to identify the position of the FD gene using genetic linkage analysis. While the disease gene has not yet been located, the exclusion of large regions of the genome will serve to guide future analyses to accelerate discovery of the FD locus.
Subjects and methods

FD FAMILIES
Patients' files from the Dysautonomia Center at the New York University Medical Center were used to obtain families with more than one dysautonomic child. Twenty-one families were identified as having two or three surviving affected subjects (fig 1) . Two additional families were chosen for linkage analysis based on a large number of unaffected sibs (family 10, fig 1) and parents who are first cousins (family 14, fig 1) . All families were from North America or Israel. The diagnosis of FD was confirmed in all cases based on standard criteria. 23 Cell lines (130 lymphoblast, two fibroblast) were established from family members shown in fig 1 (except for those marked with *). DNA 
ANALYSIS
For typing restriction fragment length polymorphisms (RFLPs), genomic DNA was isolated from cell lines, digested with restriction endonuclease, resolved by electrophoresis on 0-8% agarose gels, and transferred to Hybond N+ membranes.8 Blots were hybridised with probe DNA radioactively labelled by random priming and visualised by autoradiography as previously described. 8 For typing simple sequence repeat polymorphisms, the method described by Weber and May9 was used with the following modifications: PCR reaction volume was reduced to 10 pl using 5 to 10 ng genomic DNA, 40 ng of each primer, and about 0-25 U Taq polymerase (Boehringer). In most cases, a-32P-dGTP (3000 Ci/mmol, Amersham) was used as the labelled nucleotide. PCR conditions varied as described for the specific markers. Dried gels were subjected to autoradiography for four to 16 hours using Kodak X-OMAT AR film. ±10  ±16  4  7  ±24  ±7  ±13  8  ±20  ±22  ±16  7  6  0  ±17  ±10  ±7  ±0  ±17  ±7  ±4  ±9  ±11  ±4  ±24  ±15  ±9  ±5  ±5  ±14  ±6  ±0  ±9  ±7  ±11  ±8  ±14  ±14  ±21  ±14  ±7  ±16  ±5  ±14  ±17  ±20  ±2  ±10  ±18  ±11  ±10  ±12  ±15  ±13  ±13  ±2  ±3  ±7  ±18  ±16  ±8  ±9  ±6  ±0  ±3  ±11  ±13  ±6  ±6  ±0  ±0  ±17  ±9  ±0  ±8  ±11  ±7  ±0  ±0  ± 19  ± 12  ±7  ±7  ±2  ±16  ±11  ±15  ±7  ±6  ±9  ±3  ±10  ±2  ±2  ±6  ±12   13  14  13  13  13  13  13  13  13  13  13 intermarker intervals on other chromosomes. In no case did multipoint analysis yield a significant positive lod score ( > + 3).
It is not possible to provide an exact calculation of the percentage of the genome excluded using the pairwise and multipoint methods, owing to uncertainties concerning the exact length of the human genetic map and the 1 (1-5%) 2 (9-4%) 3 (3.5%) 4(10-3%) 5 (167%) 6(0-0%) 7 (1-2%) 8(0.1%) 9 (11-4%) 10(30-3%) 11 (4-4%) 12 (33%) 13 (0-0%) 14 (5-1%) 15 (1-1%) 16 (0 1%) 17 (0-0%) 18 Other locations are less favourable and probes mapped to these regions will be examined only after testing all of the regions indicated above. Although the EXCLUDE program appears to eliminate FD from at least 85% of the genome, it should be noted that such calculations involve numerous assumptions that overestimate the extent of the excluded regions. However, given the number of FD families available for linkage analysis, the conservative exclusion of at least 60% of the genome, and the prediction by EXCLUDE of the most probable locations, a linked marker for familial dysautonomia should be found soon.
